Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person CHRM1,3,5 bind CHRM1,3,5 antagonists

Class:Id	Reaction:9704151
_displayName	CHRM1,3,5 bind CHRM1,3,5 antagonists
_doRelease	TRUE
_timestamp	2022-05-10 17:55:10
authored	[InstanceEdit:9704054] Jassal, Bijay, 2020-10-07
compartment	[Compartment:876] plasma membrane [Compartment:984] extracellular region
created	[InstanceEdit:9704054] Jassal, Bijay, 2020-10-07
definition	Antagonist
edited	[InstanceEdit:9704054] Jassal, Bijay, 2020-10-07 [InstanceEdit:9773839] Matthews, Lisa, 2022-05-10
input	[DefinedSet:390660] CHRM1,3,5 [plasma membrane] [Homo sapiens] [DefinedSet:9704291] CHRM1,3,5 antagonists [extracellular region]
literatureReference	[LiteratureReference:390677] International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors [LiteratureReference:9704159] Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells [LiteratureReference:9704002] Antagonist binding profiles of five cloned human muscarinic receptor subtypes [LiteratureReference:9705246] Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases [LiteratureReference:9705275] Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies [LiteratureReference:9705273] Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study [LiteratureReference:9705269] Muscarinic receptor agonists and antagonists: effects on cardiovascular function [LiteratureReference:9705256] Muscarinic agonists and antagonists: effects on gastrointestinal function [LiteratureReference:9705252] Pharmacology of gastric acid inhibition [LiteratureReference:9705234] Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease [LiteratureReference:9705277] Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease [LiteratureReference:9705217] Pathophysiology and treatment of motion sickness [LiteratureReference:9705274] A Review of Myopia Control with Atropine [LiteratureReference:9705272] Management of Organophosphorus Poisoning
modified	[InstanceEdit:9704393] Jassal, Bijay, 2020-10-08 [InstanceEdit:9705218] Jassal, Bijay, 2020-10-21 [InstanceEdit:9773229] Matthews, Lisa, 2022-05-03 [InstanceEdit:9773839] Matthews, Lisa, 2022-05-10 [InstanceEdit:9773858] Matthews, Lisa, 2022-05-10 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	CHRM1,3,5 bind CHRM1,3,5 antagonists
output	[Complex:9704392] CHRM1,3,5:CHRM1,3,5 antagonists [plasma membrane] [Homo sapiens]
releaseDate	2022-06-09
reviewed	[InstanceEdit:9767610] Huddart, Rachel, 2022-03-01
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9704222] R-HSA-9704151.2
summation	[Summation:9705239] A muscarinic receptor (CHRM) antagonist is a type of anticho...
(hasEvent)	[Pathway:390648] Muscarinic acetylcholine receptors [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by CHRM1,3,5 bind CHRM1,3,5 antagonists (9704151)